drugset / Trial / NCT05700721
Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)
NaSingle-groupOpen-labelTreatment
Summary
To learn if the combination of niraparib and dostarlimab can help to control advanced cancer that has spread to the brain.
Timeline
- Start
- 2023-06-02
- Primary completion
- 2029-12-31
- Completion
- 2029-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dostarlimab | Monoclonal antibody | — | Intravenous |
| Subject | Niraparib | Small molecule | — | Oral |